Please login to the form below

Not currently logged in
Email:
Password:

Article 50

This page shows the latest Article 50 news and features for those working in and with pharma, biotech and healthcare.

No deal or revoke looming as fourth vote on Brexit nears

No deal or revoke looming as fourth vote on Brexit nears

So weeks after the EU agreed an extension of Article 50 to 31 October – now just over 160 days away – there seems to have been little progress, despite appeals by President ... Number 10 had been informally saying that if the deals doesn’t get

Latest news

More from news
Approximately 0 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Leave or remain? Winning the employee referendum Leave or remain? Winning the employee referendum

    killer question: ‘Should I stay or should I go?’ Our decision to trigger the employee equivalent of Article 50 will normally be influenced by our experiences with our current employer. ... We all know you. can’t run a business on 50% turnover, but

  • The Patient Safety Challenge The Patient Safety Challenge

    The goal that the WHO’s document set is to ‘gain worldwide commitment and action to reduce severe, avoidable medication-related harm by 50% in the next five years’. ... International research collaboration. In this article, we describe a programme

  • Macron, Merkel and May: implications of the 2017 elections for the life science industry Macron, Merkel and May: implications of the 2017 elections for the life science industry

    50 negotiations, which could result in a new Government with a different set of policy priorities and an alternative approach to Brexit. ... However, the Chancellor, Philip Hammond, welcomed the CBI’s call for an ‘indefinite’ transition period

  • Brexit: the facts (and the alternative facts) Brexit: the facts (and the alternative facts)

    How Brexit affects pharma. The British Government submitted Article 50 in March 2017, formerly giving giving notice its intent to leave the EU.

  • Brexit: Implications for the pharma industry Brexit: Implications for the pharma industry

    Notice under Article 50 was given at the end of March 2017, triggering the start of the two-year period during which the UK’s withdrawal from the EU will be

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...